GENPREX (NASDAQ:GNPX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of GENPREX (NASDAQ:GNPX) to a sell rating in a research report released on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of GENPREX in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, GENPREX currently has a consensus rating of “Sell”.

GENPREX Stock Performance

Shares of GENPREX stock opened at $0.28 on Friday. GENPREX has a 52 week low of $0.14 and a 52 week high of $3.97. The business has a 50 day moving average of $0.23 and a 200 day moving average of $0.25.

GENPREX (NASDAQ:GNPX) last posted its earnings results on Thursday, August 14th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.54. As a group, equities research analysts forecast that GENPREX will post -5.7 EPS for the current fiscal year.

GENPREX Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.